The U.S. life sciences sector has felt the impact of global macroeconomic headwinds and saw venture capital funding in 2022 drop 28.2% as a result. The industry is better prepared to withstand upcoming volatility as there is still elevated interest in life sciences and dry powder sitting on the sidelines.
.jpg)